Rafarma Pharmaceuticals(OTC) RAFA

Rafarma Pharmaceuticals, Inc. is a diversified pharmaceutical enterprise focused on manufacturing and distributing a variety of medicinal products, including generic antibiotics and specialized drugs in the Russian market. The company offers a comprehensive portfolio that includes anti-cancer medications and innovative treatments for various health conditions.

Products and Services

• Generic antibiotics and specialized drugs
• Innovative anti-cancer medications
• Medical cannabis suppositories for inflammatory bowel disease

Growth Outlook

• Recent quarterly revenue reached $308,000, showing potential for growth
• Trailing twelve months (TTM) revenue of $8.34 million indicates a solid market presence
• Strategic partnerships, like the one with PlantEXT Ltd., enhance product offerings

Financial Highlights

• Net income for Q4 2026 was $82,000, reflecting operational efficiency
• TTM net profit margin stands at 2.42%, indicating profitability
• Current ratio of 1.09 suggests good short-term financial health

Rafarma Pharmaceuticals, Inc. operates within the healthcare sector, specifically in drug manufacturing, and has established a significant footprint in the Russian market. The company’s diverse product range, including both generic and specialized medications, positions it well to meet the growing demand for pharmaceutical products. The recent collaboration with PlantEXT Ltd. to develop medical cannabis products highlights Rafarma's commitment to innovation and addressing emerging health needs. Financially, the company has demonstrated resilience, with a recent quarterly revenue of $308,000 and a TTM revenue of $8.34 million. The net income of $82,000 in the latest quarter showcases the company's ability to generate profit, while a net profit margin of 2.42% indicates effective cost management. The current ratio of 1.09 reflects a stable liquidity position, suggesting that Rafarma can meet its short-term obligations. Overall, Rafarma Pharmaceuticals, Inc. presents a compelling opportunity for investors interested in the pharmaceutical sector, particularly in the context of its growth potential and financial stability.